[Analysis of the Cochrane Review: Anti-vascular Endothelial Growth Factor for Prevention of Postoperative Vitreous Cavity Hemorrhage after Vitrectomy for Proliferative Diabetic Retinopathy. Cochrane Database Syst Rev. 2015;8:CD008214.]

Authors:
David Cordeiro Sousa
David Cordeiro Sousa
Hospital Santa Maria - Lisbon Academic Medical Center
Ines Leal
Ines Leal
Hospital de Santa Maria-Lisbon Academic Medical Center
Joao Costa
Joao Costa
Laboratório de Etologia Aplicada e Bem-Estar Animal (LETA)

Acta Med Port 2017 Aug 31;30(7-8):513-516. Epub 2017 Aug 31.

Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal; Cochrane Portugal. Lisboa. Portugal.

Postoperative vitreous hemorrhage is a complication following vitrectomy for proliferative diabetic retinopathy, delaying visual recovery and making fundus examination and disease follow-up more difficult. Anti-vascular endothelial growth factor drugs such as bevacizumab, when injected in the vitreous cavity, reduce vascular proliferation and their use has been proposed to reduce the incidence of postoperative vitreous hemorrhage. The authors of this Cochrane systematic review evaluated all randomized controlled trials on the pre- or intraoperative use of anti-vascular endothelial growth factor to reduce postoperative vitreous hemorrhage occurrence after vitrectomy in patients with proliferative diabetic retinopathy. The results suggested that the use of intravitreal bevacizumab was effective in reducing early postoperative vitreous hemorrhage (i.e. at four weeks) occurrence, with a good safety profile. This work aims to summarize and discuss the findings and clinical implications of this Cochrane systematic review.

Download full-text PDF

Source
August 2017
6 Reads

Publication Analysis

Top Keywords

postoperative vitreous
20
vitreous hemorrhage
16
anti-vascular endothelial
12
endothelial growth
12
diabetic retinopathy
12
proliferative diabetic
12
growth factor
12
vitreous cavity
8
vitrectomy proliferative
8
systematic review
8
cochrane systematic
8
vitreous
6
hemorrhage
5
postoperative
5
intraoperative anti-vascular
4
pre- intraoperative
4
controlled trials
4
review evaluated
4
randomized controlled
4
evaluated randomized
4

Similar Publications

Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Cochrane Database Syst Rev 2015 Aug 7(8):CD008214. Epub 2015 Aug 7.

Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, UK, SR2 9HP.

Background: Postoperative vitreous cavity haemorrhage (POVCH) is a significant complication following vitrectomy for proliferative diabetic retinopathy (PDR). It delays visual recovery and can make further treatment difficult if the view of the fundus is significantly obscured. A number of interventions to reduce the incidence of POVCH have been proposed, including the perioperative use of anti-vascular endothelial growth factor (anti-VEGF). Read More

View Article
August 2015

Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Cochrane Database Syst Rev 2011 May 11(5):CD008214. Epub 2011 May 11.

Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, UK, SR2 9HP.

Background: Postoperative vitreous cavity haemorrhage (POVCH) is a significant complication following vitrectomy for proliferative diabetic retinopathy (PDR). It delays visual recovery and can make further treatment difficult if the view of the fundus is significantly obscured. A number of interventions to reduce the incidence of POVCH have been proposed, including the perioperative use of anti-vascular endothelial growth factor (anti-VEGF). Read More

View Article
May 2011

Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage.

Retina 2010 Nov-Dec;30(10):1646-50

Division of Vitreoretinal Surgery, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia.

Purpose: The purpose of this study was to evaluate the role of bevacizumab (Avastin), an antivascular endothelial growth factor agent, injected at the end of surgery for preventing postoperative recurrent vitreous hemorrhage in patients undergoing vitrectomy for diabetic eye disease.

Methods: This was a retrospective, comparative, and nonrandomized study on a consecutive series of patients who underwent vitrectomy for diabetic eye disease. Recurrence of postoperative vitreous hemorrhage was compared in patients with and without intravitreal 1. Read More

View Article
February 2011

Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.

Middle East Afr J Ophthalmol 2013 Jan-Mar;20(1):51-5

Osaka Rosai Hospital, Clinical Research Center for Occupational Sensory Organ Disability, Kita-Ku, Sakai, Japan.

Purpose: To evaluate the effect of preoperative intravitreal bevacizumab (IVB) on surgical procedures, visual prognosis, and postoperative complications, especially postoperative vitreous hemorrhage, in cases with proliferative diabetic retinopathy (PDR).

Materials And Methods: Seventy-one eyes of 54 consecutive patients (23 eyes of 18 women, 48 eyes of 36 men) were investigated in this study. Twenty-five eyes received IVB one to 30 days before the vitrectomy (Bevacizumab Group) and the other 46 eyes had the vitrectomy alone (Control Group). Read More

View Article
January 2014